ARTICLE | Company News
Zambon, CSL deal
January 20, 2017 7:59 PM UTC
Zambon granted CSL’s Seqirus unit exclusive rights to develop and commercialize Parkinson’s disease drug Xadago safinamide in Australia and New Zealand. Zambon has exclusive rights from Newron Pharmac...
BCIQ Target Profiles